Further developments in the literature on RAAS inhibitors and COVID-19.
作者信息
Quinn Kieran L, Fralick Michael, Zipursky Jonathan S, Stall Nathan M
机构信息
General internist and palliative care physician, Department of Medicine, University of Toronto; Division of General Internal Medicine and Geriatrics, Sinai Health System; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ont.
Clinician scientist, Department of Medicine, University of Toronto; Division of General Internal Medicine and Geriatrics, Sinai Health System, Toronto, Ont.
出版信息
CMAJ. 2020 Jun 29;192(26):E727. doi: 10.1503/cmaj.76076.
Abstract
摘要
相似文献
1
Further developments in the literature on RAAS inhibitors and COVID-19.关于肾素-血管紧张素-醛固酮系统（RAAS）抑制剂与2019冠状病毒病（COVID-19）的文献的进一步进展。
CMAJ. 2020 Jun 29;192(26):E727. doi: 10.1503/cmaj.76076.
2
Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?2019冠状病毒病（COVID-19）：血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂是否具有双相效应？
J Am Heart Assoc. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1.
3
Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.肾素-血管紧张素系统抑制剂对新型冠状病毒肺炎中2019冠状病毒感染及肺损伤的潜在差异影响
Hypertens Res. 2020 Aug;43(8):837-840. doi: 10.1038/s41440-020-0478-1. Epub 2020 May 20.
4
Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.肾素-血管紧张素-醛固酮系统抑制剂治疗高血压患者可降低COVID-19死亡率：一项荟萃分析
Hypertension. 2020 Aug;76(2):e13-e14. doi: 10.1161/HYPERTENSIONAHA.120.15572. Epub 2020 May 27.
5
COVID-19: A Concern for Cardiovascular Disease Patients.COVID-19：心血管疾病患者的关注点。
Cardiovasc Toxicol. 2020 Oct;20(5):443-447. doi: 10.1007/s12012-020-09596-0. Epub 2020 Jul 29.
6
What solid organ transplant healthcare providers should know about renin-angiotensin-aldosterone system inhibitors and COVID-19.实体器官移植医护人员应该了解的肾素-血管紧张素-醛固酮系统抑制剂与 COVID-19 相关知识。
Clin Transplant. 2020 Jul;34(7):e13991. doi: 10.1111/ctr.13991. Epub 2020 Jun 15.
7
Renin-angiotensin system and SARS-CoV-2 interaction: underlying mechanisms and potential clinical implications.肾素-血管紧张素系统与新型冠状病毒2的相互作用：潜在机制及临床意义
Gen Physiol Biophys. 2020 May;39(3):203-204. doi: 10.4149/gpb_2020019.
8
Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.2019冠状病毒病（COVID-19）：血管紧张素转换酶抑制剂、血管紧张素II受体阻滞剂与心血管疾病
Med J Aust. 2020 Jun;212(11):502-503.e1. doi: 10.5694/mja2.50622. Epub 2020 May 21.
9
A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.肾素-血管紧张素-醛固酮系统抑制剂与新型冠状病毒肺炎关系的Meta分析
Am J Cardiol. 2020 Sep 1;130:159-161. doi: 10.1016/j.amjcard.2020.05.038. Epub 2020 Jun 2.
10
[Hypertension and RAAS inhibition in times of COVID-19 - current recommendations of the European Society of Hypertension.].[2019冠状病毒病时期的高血压与肾素-血管紧张素-醛固酮系统抑制——欧洲高血压学会的当前建议。]
MMW Fortschr Med. 2020 May;162(9):67-69. doi: 10.1007/s15006-020-0483-y.
本文引用的文献
1
Good things come in threes (and sometimes fours): Update on renin-angiotensin-aldosterone system inhibitors and COVID-19.好事成三（有时成四）：肾素-血管紧张素-醛固酮系统抑制剂与2019冠状病毒病的最新情况
CMAJ. 2020 Jun 1;192(22):E611. doi: 10.1503/cmaj.75720.
2
Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与 COVID-19 住院风险的相关性：一项基于病例的队列研究
Lancet. 2020 May 30;395(10238):1705-1714. doi: 10.1016/S0140-6736(20)31030-8. Epub 2020 May 14.
3
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.心血管疾病、药物治疗与新冠病毒感染相关死亡率
N Engl J Med. 2020 Jun 18;382(25):e102. doi: 10.1056/NEJMoa2007621. Epub 2020 May 1.
4
Renin-angiotensin-aldosterone system inhibitors and COVID-19.肾素-血管紧张素-醛固酮系统抑制剂与2019冠状病毒病
CMAJ. 2020 May 19;192(20):E553-E554. doi: 10.1503/cmaj.200619. Epub 2020 Apr 24.
Zotero 插件